GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Myrexis Inc (OTCPK:MYRX) » Definitions » ROE %

Myrexis (Myrexis) ROE %

: -48.75% (As of Jun. 2013)
View and export this data going back to 2013. Start your Free Trial

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Myrexis's annualized net income for the quarter that ended in Jun. 2013 was $-0.60 Mil. Myrexis's average Total Stockholders Equity over the quarter that ended in Jun. 2013 was $1.24 Mil. Therefore, Myrexis's annualized ROE % for the quarter that ended in Jun. 2013 was -48.75%.

The historical rank and industry rank for Myrexis's ROE % or its related term are showing as below:

MYRX's ROE % is not ranked *
in the Diversified Financial Services industry.
Industry Median: 0.77
* Ranked among companies with meaningful ROE % only.

Myrexis ROE % Historical Data

The historical data trend for Myrexis's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myrexis Annual Data
Trend Jun08 Jun09 Jun10 Jun11 Jun12 Jun13
ROE %
Premium Member Only -73.46 -27.70 -28.91 -30.11 -25.67

Myrexis Quarterly Data
Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13
ROE % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -19.34 -15.59 -22.85 -31.02 -48.75

Competitive Comparison

For the Shell Companies subindustry, Myrexis's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Myrexis ROE % Distribution

For the Diversified Financial Services industry and Financial Services sector, Myrexis's ROE % distribution charts can be found below:

* The bar in red indicates where Myrexis's ROE % falls into.



Myrexis ROE % Calculation

Myrexis's annualized ROE % for the fiscal year that ended in Jun. 2013 is calculated as

ROE %=Net Income (A: Jun. 2013 )/( (Total Stockholders Equity (A: Jun. 2012 )+Total Stockholders Equity (A: Jun. 2013 ))/ count )
=-11.621/( (89.372+1.163)/ 2 )
=-11.621/45.2675
=-25.67 %

Myrexis's annualized ROE % for the quarter that ended in Jun. 2013 is calculated as

ROE %=Net Income (Q: Jun. 2013 )/( (Total Stockholders Equity (Q: Mar. 2013 )+Total Stockholders Equity (Q: Jun. 2013 ))/ count )
=-0.604/( (1.315+1.163)/ 2 )
=-0.604/1.239
=-48.75 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Jun. 2013) net income data. ROE % is displayed in the 30-year financial page.


Myrexis  (OTCPK:MYRX) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Jun. 2013 )
=Net Income/Total Stockholders Equity
=-0.604/1.239
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-0.604 / 0)*(0 / 1.4485)*(1.4485 / 1.239)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*1.1691
=ROA %*Equity Multiplier
=N/A %*1.1691
=-48.75 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Jun. 2013 )
=Net Income/Total Stockholders Equity
=-0.604/1.239
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-0.604 / -0.604) * (-0.604 / -0.612) * (-0.612 / 0) * (0 / 1.4485) * (1.4485 / 1.239)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 0.9869 * N/A % * 0 * 1.1691
=-48.75 %

Note: The net income data used here is four times the quarterly (Jun. 2013) net income data. The Revenue data used here is four times the quarterly (Jun. 2013) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Myrexis ROE % Related Terms

Thank you for viewing the detailed overview of Myrexis's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Myrexis (Myrexis) Business Description

Traded in Other Exchanges
N/A
Address
630 Fifth Avenue, Suite 2260, New York, NY, USA, 10020
Myrexis Inc is engaged in evaluating strategic alternatives, such as identifying, evaluating and making financial investments in life sciences assets.
Executives
Xstelos Corp. 10 percent owner 630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020
Steven D Scheiwe director 1741 EDGEFIELD LANE, ENCINITAS CA 92024
Pearce Michael Cooper director 213 RHODODENDRON DRIVE, CHAPEL HILL NC 27517
Jonathan Couchman director, officer: Chairman, President and CEO 630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020
John T Henderson director 320 WAKARA WAY, SALT LAKE CITY UT 84108
First Eagle Investment Management, Llc 10 percent owner 1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105
Jason Aryeh director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Gerald P. Belle director 320 WAKARA WAY, SALT LAKE CITY UT 84108
David W Gryska director, officer: Chief Operating Officer 749 N MARY AVE, SUNNYVALE CA 94085
Richard B Brewer director, officer: President and CEO C/O DENDREON CORP, 3005 1ST AVE, SEATTLE WA 98121
Timothy R Franson director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Dennis Langer director C/O PETER TSOFLIAS, BLANK ROME LLP, ONE LOGAN SQUARE, FL 9, PHILADELPHA PA 19103
Robert Forrester director C/O COMBINATORX, INCORPORATED, 245 FIRST STREET, 3RD FLOOR, CAMBRIDGE MA 02142
Adrian N Hobden director, officer: President and CEO 320 WAKARA WAY, SALT LAKE CITY UT 84108
W Wayne Laslie officer: Chief Operating Officer 320 WAKARA WAY, SALT LAKE CITY UT 84108

Myrexis (Myrexis) Headlines